Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N6SG | ISIN: US8693671021 | Ticker-Symbol: S09
Tradegate
31.03.25
21:09 Uhr
0,630 Euro
-0,050
-7,35 %
1-Jahres-Chart
SUTRO BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
SUTRO BIOPHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,5800,60022:00
0,5800,61522:00

Aktuelle News zur SUTRO BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.03.Sutro Biopharma stock rating downgraded at H.C. Wainwright3
17.03.Sutro Biopharma :REFRaME-O1 Trial Data On Luvelta Shows Promise In Platinum-Resistant Ovarian Cancer13
15.03.Sutro Biopharma, Inc.: Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 20253
14.03.Jefferies cuts Sutro Biopharma target to $8, maintains Buy13
14.03.Oppenheimer cuts Sutro Biopharma stock rating to Perform1
SUTRO BIOPHARMA Aktie jetzt für 0€ handeln
14.03.Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline2
14.03.Truist maintains Buy on Sutro Biopharma, removes price target5
14.03.Sutro drops as portfolio review leads to downgrades14
14.03.Sutro puts lead ADC on hold, cuts staff and changes CEO-
14.03.BofA cuts Sutro Biopharma stock rating, slashes target to $15
14.03.Sutro discards CEO, 50% of staff, sole clinical-stage ADC and manufacturing site to save cash3
14.03.Wedbush cuts Sutro Biopharma stock rating, slashes target to $24
14.03.Sutro Biopharma stock rating cut to Market Perform by JMP14
13.03.SUTRO BIOPHARMA, INC. - 10-K, Annual Report2
13.03.SUTRO BIOPHARMA, INC. - 8-K, Current Report1
13.03.Sutro Biopharma GAAP EPS of -$2.96 misses by $0.06, revenue of $62.04M beats by $2.84M2
13.03.Sutro Biopharma, Inc.: Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights694- Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition - - Cash, cash equivalents...
► Artikel lesen
13.03.Sutro Biopharma, Inc.: Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline133- Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner - - Three INDs for...
► Artikel lesen
27.02.SUTRO BIOPHARMA, INC. - S-8, Securities to be offered to employees in employee benefit plans4
11.12.24Expert Outlook: Sutro Biopharma Through The Eyes Of 6 Analysts21
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1